期刊
NEUROMUSCULAR DISORDERS
卷 33, 期 4, 页码 315-318出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.nmd.2023.02.008
关键词
Fatty acid oxidation disorders; Long -chain 3-hydroxyacyl-CoA; dehydrogenase deficiency; Multisystem inflammatory syndrome in; children (MISC); Retinopathy; Rhabdomyolysis; Triheptanoin
Early-onset long-chain 3-hydroxyacyl-coenzyme A dehydrogenase (LCHAD) deficiency is a fatty acid beta oxidation disorder with a poor prognosis. Triheptanoin, an anaplerotic oil with odd-chain fatty acids, can significantly reduce the frequency and severity of rhabdomyolysis in patients with LCHAD deficiency. In this case report, a female patient with LCHAD deficiency experienced a decrease in rhabdomyolysis episodes and hospitalization days after starting triheptanoin treatment, although retinopathy progression was not altered.
Early-onset long-chain 3-hydroxyacyl-coenzyme A dehydrogenase (LCHAD) deficiency is a fatty acid beta oxidation disorder with a poor prognosis. Triheptanoin, an anaplerotic oil with odd-chain fatty acids can improve the disease course. The female patient presented here was diagnosed at the age of 4 months, and treatment was started as fat restriction, frequent feeding, and standard medium-chain triglyceride supplementation. In follow-up, she had frequent rhabdomyolysis episodes ( similar to 8 per year). At the age of six, she had 13 episodes in 6 months, and triheptanoin was started as part of a compassionate use program. Following unrelated hospital stays due to multisystem inflammatory syndrome in children and a bloodstream infection, she had only 3 rhabdomyolysis episodes, and hospitalized days decreased from 73 to 11 during her first year with triheptanoin. Triheptanoin drastically decreased the frequency and severity of rhabdomyolysis, but progression of retinopathy was not altered.(c) 2023 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据